Stephanie Monaghan O’Brien

Stephanie O’Brien has been a member of the Morningside investment team since 1997, working with venture-backed companies focused on novel science. Ms. O’Brien has been a director of numerous companies developing drugs across a broad spectrum of therapeutic areas, including oncology and immunotherapy, and has extensive experience providing operational and management guidance torapidly growing life science and technology companies. She has served on public and private company boards, including Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), Aduro Biotech, Inc.(NASDAQ:ADRO), I-Behavior, Inc., Canopy Education, Inc., Natural Polymer International Corp., Linc Global, Inc., Vioptix, Inc., and 2020, Inc.

Ms. O’Brien has also worked on M&A deals and financings for public and private companies such as DNAtrix, Inc., Dendreon Corporation, BioVex Group, Inc., Stealth Biotherapeutics Inc. and Sohu.com. Prior to Morningside, Ms. O’Brien spent nine years as a corporate lawyer with Hale and Dorr in the Boston and Washington, D.C. offices, working primarily with venture capital finance and start-up companies. She received her A.B., cum laude, from Harvard College and her J.D. from New York University School of Law.